Skip to content

Danqi Qinghua granules improve GLP-1 levels in overweight/obese patients with type 2 diabetes: a double-blind randomized controlled study protocol

Danqi Qinghua granules improve GLP-1 levels in overweight/obese patients with type 2 diabetes: a double-blind randomized controlled study protocol

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067708
Enrollment
Unknown
Registered
2023-01-18
Start date
2023-01-22
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overweight/obese patients with type 2 diabetes

Interventions

Treatment Group:Danqi Qinghua granules (1 dose per day, 200mL of boiled water)
Control group:Danqi Qinghua granules placebo (1 dose per day, 200mL of boiled water)

Sponsors

Ersha Island Hospital, Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes mellitus combined with overweight and obesity (BMI >= 24 kg/m2) or central obesity (waist circumference >= 90 cm in men and >= 85 cm in women); 2. Medical history < 5 years; 3. Aged 18-70 years; 4. Be willing to obey the doctor's treatment plan and cooperate with follow-up; 5. All patients will be included after completing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mentally ill persons who cannot understand the nature and scope of the study or cannot comply with medical advice; 2. Acute complications such as diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, and diabetic lactic acidosis; 3. Patients with malignant tumors and severe insufficiency of heart, liver and kidney; 4. Pregnant or lactating; 5. Those who have used GLP-1RA and DPP-Vi in the past two weeks; 6. Those who are lactose intolerant.

Design outcomes

Primary

MeasureTime frame
Fasting GLP-1 level;

Secondary

MeasureTime frame
Fasting insulin;Glycated hemoglobin (HbA1c);fasting blood glucose (FBG);blood glucose 2 hours after meals (2hPG);blood lipids;Body mass;waist-hip ratio;body fat detection;TCM symptom points;

Countries

China

Contacts

Public ContactXianyu Tang

Ersha Island Hospital, Guangdong Provincial Hospital of Chinese Medicine

13922212818@139.com+86 13922212818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026